Trials / Conditions / ALK Fusion Protein Expression
ALK Fusion Protein Expression
5 registered clinical trials studyying ALK Fusion Protein Expression — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC NCT05950139 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Po NCT05186506 | Sichuan University | Phase 2 |
| Unknown | Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) NCT04921553 | Centre Leon Berard | — |
| Withdrawn | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Ca NCT03868423 | Sameek Roychowdhury | Phase 2 |
| Terminated | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV NCT02587650 | University of California, San Francisco | Phase 2 |